Home › Blood Cancers › Minnesota
Blood Cancers clinical trials in Minnesota
17 studies for Blood Cancers are looking for participants at sites in Minnesota.
Cities in Minnesota
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Riverwood Healthcare Center, Aitkin
- Mayo Clinic Health System in Albert Lea, Albert Lea
- Essentia Health - Baxter Clinic, Baxter
- and 48 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Oct 2, 2026 · NCT05334069Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- Sanford Joe Lueken Cancer Center, Bemidji
- Minnesota Oncology - Burnsville, Burnsville
- Mercy Hospital, Coon Rapids
- and 24 more
RecruitingObservational study
All ages · All sexes · Updated Sep 17, 2026 · NCT04242095Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Mayo Clinic, Rochester
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 3, 2026 · NCT04588922Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Minnesota, Minneapolis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT07007312PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
- University of Minnesota, Minneapolis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT06665100Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- Masonic Cancer Center, University of Minnesota, Minneapolis
Recruiting
All ages · All sexes · Updated May 8, 2026 · NCT01451502CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Mayo Clinic, Rochester
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 16, 2026 · NCT03328078MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
- University of Minnesota Masonic Cancer Center, Minneapolis
RecruitingPhase 2
Up to age 60 · All sexes · Updated Apr 6, 2026 · NCT05735717Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking Study
- Mayo Clinic, Rochester
RecruitingObservational study
All ages · All sexes · Updated Apr 1, 2026 · NCT02457962Avera Cancer Sequencing and Analytics Protocol (ASAP)
- Avera Cancer Institute - Marshall, Marshall
RecruitingObservational study
Ages 18 and older · All sexes · Updated Mar 27, 2026 · NCT05142033Role of Gut Microbiome in Cancer Therapy
- Mayo Clinic in Rochester, Rochester
RecruitingObservational study
Ages 18 to 99 · All sexes · Updated Mar 16, 2026 · NCT05112614A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- University of Minnesota, Minneapolis
- Mayo Clinic - Rochester, Rochester
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 13, 2026 · NCT05735184Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
- Mayo Clinic in Rochester, Rochester
Recruiting
Ages 18 and older · All sexes · Updated Feb 23, 2026 · NCT02958462CIBMTR Research Database
- Center for International Blood and Marrow Transplant Research, Minneapolis
RecruitingObservational study
All ages · All sexes · Updated Aug 12, 2025 · NCT01166009IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- University of Minnesota, Minneapolis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 3, 2025 · NCT06119685Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
- University of Minnesota, Minneapolis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 15, 2025 · NCT06462365Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Children's Hospital and Clinics of Minnesota, Minneapolis
RecruitingPhase 1
Ages 1 to 21 · All sexes · Updated Dec 6, 2024 · NCT05476770From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.